International Society of Liquid Biopsy shared a post on X:
“ISLB Research Highlight! ctDNA and Beyond to Serve Immunotherapy.
Key Insights from ESMOImmuno24:
- Stable blood DNA methylation profiles may serve as reliable biomarkers in NSCLC (Abstract 24P).
- Increased somatic mutation rates and NLR values correlate with disease progression in ICI-treated NSCLC (Abstract 28P).
- ctDNA levels predict survival outcomes in metastatic uveal melanoma (Abstract 25P).
- Peripheral immune cell analysis may improve response prediction for PD-1 inhibitors in head and neck cancers (Abstract 27P).
- Changes in neutrophil/CD4+ T cell balance linked to immune-related adverse events (irAEs) (Abstract 37P).
Liquid biopsy is redefining immuno-oncology, but prospective trials are needed!
Read the analysis by our esteemed Professor Umberto Malapelle based on recent results presented during ESMOImmuno2024.”
More posts featuring International Society of Liquid Biopsy.